Contraception counseling for women with premenstrual dysphoric disorder (PMDD): current perspectives

IF 1.8 Q3 OBSTETRICS & GYNECOLOGY
Andrea J. Rapkin, Yelena Korotkaya, Kathrine C Taylor
{"title":"Contraception counseling for women with premenstrual dysphoric disorder (PMDD): current perspectives","authors":"Andrea J. Rapkin, Yelena Korotkaya, Kathrine C Taylor","doi":"10.2147/OAJC.S183193","DOIUrl":null,"url":null,"abstract":"Abstract Premenstrual Dysphoric Disorder (PMDD) is a severe form of premenstrual syndrome (PMS) affecting up to 7% of reproductive age women. Women with PMDD are of reproductive age; therefore, contraception and treatment of PMDD are important considerations. The disorder as described in the DSM-V is characterized by moderate to severe psychological, behavioral and physical symptoms beginning up to two weeks prior to menses, resolving soon after the onset of menstruation and significantly interfering with daily functioning. PMDD develops in predisposed individuals after they are exposed to progesterone at the time of ovulation. It has been hypothesized that PMDD is in part attributable to luteal phase abnormalities in serotonergic activity and to altered configuration of ℽ-aminobutyric acid subunit A (GABAA) receptors in the brain triggered by the exposure to the neuroactive steroid progesterone metabolite, allopregnanolone (Allo). A large body of evidence suggests that selective serotonin reuptake inhibitors (SSRIs) can be effective in the treatment of PMDD. Combined hormonal contraceptive (CHC) pills, specifically the 20 mcg ethinyl estradiol/3mg drospirenone in a 24/4 extended cycle regimen has been shown to significantly improve the emotional and physical symptoms of PMDD. Other combined monophasic, extended cycle hormonal contraceptive pills with less androgenic progestins may also be helpful, although not well studied. Copper intrauterine devices (IUDs) are recommended for those not seeking hormonal contraceptives. Progestin-only methods including the progestin-only pill (POP), levonorgestrel (LNG) IUD, etonorgestrel implant or depot medroxyprogesterone acetate (DMPA) have the potential to negatively affect mood symptoms for women with or without baseline mood disorders, including PMDD. Careful counseling and close follow-up is recommended for patients with PMDD seeking these contraceptive methods.","PeriodicalId":74348,"journal":{"name":"Open access journal of contraception","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2019-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/OAJC.S183193","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open access journal of contraception","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/OAJC.S183193","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 5

Abstract

Abstract Premenstrual Dysphoric Disorder (PMDD) is a severe form of premenstrual syndrome (PMS) affecting up to 7% of reproductive age women. Women with PMDD are of reproductive age; therefore, contraception and treatment of PMDD are important considerations. The disorder as described in the DSM-V is characterized by moderate to severe psychological, behavioral and physical symptoms beginning up to two weeks prior to menses, resolving soon after the onset of menstruation and significantly interfering with daily functioning. PMDD develops in predisposed individuals after they are exposed to progesterone at the time of ovulation. It has been hypothesized that PMDD is in part attributable to luteal phase abnormalities in serotonergic activity and to altered configuration of ℽ-aminobutyric acid subunit A (GABAA) receptors in the brain triggered by the exposure to the neuroactive steroid progesterone metabolite, allopregnanolone (Allo). A large body of evidence suggests that selective serotonin reuptake inhibitors (SSRIs) can be effective in the treatment of PMDD. Combined hormonal contraceptive (CHC) pills, specifically the 20 mcg ethinyl estradiol/3mg drospirenone in a 24/4 extended cycle regimen has been shown to significantly improve the emotional and physical symptoms of PMDD. Other combined monophasic, extended cycle hormonal contraceptive pills with less androgenic progestins may also be helpful, although not well studied. Copper intrauterine devices (IUDs) are recommended for those not seeking hormonal contraceptives. Progestin-only methods including the progestin-only pill (POP), levonorgestrel (LNG) IUD, etonorgestrel implant or depot medroxyprogesterone acetate (DMPA) have the potential to negatively affect mood symptoms for women with or without baseline mood disorders, including PMDD. Careful counseling and close follow-up is recommended for patients with PMDD seeking these contraceptive methods.
经前焦虑症(PMDD)妇女的避孕咨询:当前观点
摘要月经前综合征(PMDD)是一种严重的经前综合征,影响多达7%的育龄妇女。患有PMDD的妇女已达到生育年龄;因此,预防和治疗PMDD是重要的考虑因素。DSM-V中描述的这种疾病的特征是在月经前两周开始出现中度至重度的心理、行为和身体症状,在月经开始后很快消失,并严重干扰日常功能。易感个体在排卵时暴露于黄体酮后会出现PMDD。据推测,PMDD在一定程度上可归因于5-羟色胺能活性的黄体期异常和ℽ-脑中氨基丁酸亚单位A(GABAA)受体,由暴露于神经活性类固醇孕酮代谢产物异孕纳龙(Allo)触发。大量证据表明,选择性血清素再摄取抑制剂(SSRIs)可以有效治疗PMDD。激素避孕药(CHC),特别是20 mcg乙炔雌二醇/3mg屈螺酮,采用24/4延长周期方案,已被证明可显著改善PMDD的情绪和身体症状。其他含有较少雄激素的单相、长周期激素避孕药也可能有帮助,尽管研究不充分。建议那些不寻求激素避孕药的人使用铜宫内节育器。仅使用孕激素的方法,包括仅使用孕激素药丸(POP)、左炔诺孕酮(LNG)宫内节育器、依托孕烯植入物或储备醋酸甲羟孕酮(DMPA),有可能对患有或不患有基线情绪障碍(包括PMDD)的女性的情绪症状产生负面影响。建议对寻求这些避孕方法的PMDD患者进行仔细的咨询和密切的随访。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信